Y332D, a bispecific antibody that simultaneously blockades VEGF and TGF‐β, counteracted negative RT effects that are attributed to the upregulation of TGF‐β and VEGF, as well as further enhanced the immunostimulatory effects of RT, thereby reprograming the TME from immune “cold” to inflamed state and forming an effective in‐situ vaccine that eradicate local tumor and augment abscopal effects. The gene discussed is TGFB1; the disease is neoplasm.